Brief: Jacobio Pharmaceuticals Says Abbvie Sent Termination Notice Of Deal For Development Of Shp2 Inhibitors
04/07/2023 16:10
July 4 (Reuters) - Jacobio Pharmaceuticals Group Co Ltd
1167.HK :
* ABBVIE DELIVERED TERMINATION NOTICE OF PARTIES' LICENSE
AND
COLLABORATION AGREEMENT FOR DEVELOPMENT OF SHP2 INHIBITORS
* FOLLOWING TERMINATION, CO WILL REGAIN GLOBAL RIGHTS
PREVIOUSLY
GRANTED TO ABBVIE TO SUCH SHP2 INHIBITORS
Further company coverage: 1167.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jacobio Pharmaceuticals
See all newsBrief: Jacobio Pharmaceuticals Appoints Xiaojie Wang As Vice Chairperson
China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Brief: Jacobio Pharmaceuticals Group Posts H1 Net Income Attributable RMB 600.6 Million
Brief: Jacobio Pharmaceuticals Expects HY Net Profit Of Not Less Than RMB600 Million
HK-listed Jacobio Pharmaceuticals climbs on share buyback plan